July 30, 2015.
In this video
, GlaxoSmithKline CFO Simon Dingemans relays the company's Q2 2015 results, rhe first since the Novartis transaction closed. Despite a slide in the sales of lung drug Advair and lower profit margins following a business revamp, Dingemans says sales rose during the period and that newly acquired businesses are performing in line with expectations.
http://www.3bnexus.com/portal/video/6hdb24abf34c8cc
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.